<DOC>
	<DOCNO>NCT00321373</DOCNO>
	<brief_summary>The purpose study evaluate immune response safety influenza vaccine candidate without adjuvant compare Fluarixâ„¢ administer intramuscularly elderly age 60 year old .</brief_summary>
	<brief_title>Study Evaluate Influenza Vaccine Candidate</brief_title>
	<detailed_description>Subjects randomize 3 group follow 6 month 4 schedule contact per subject . The immune response evaluate day 0 , 21 180 vaccination . The safety evaluation involve follow-up solicit local general sign symptom , unsolicited adverse event serious adverse event . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : A male female age 60 year old time vaccination . Subjects investigator believe comply requirement protocol Written inform consent obtain subject . Free acute aggravation health status establish clinical examination enter study . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) within 30 day precede administration study vaccine , plan use study period . Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within three month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 30 day vaccination . History hypersensivity previous dose influenza vaccine . Previous vaccination influenza within 9 month prior enrollment . History confirm influenza infection within last 12 month . History allergy reaction likely exacerbate component vaccine ( ) Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza vaccine</keyword>
</DOC>